Scarica l'app Stockscreener
5.04
2.44%
0.12
Dopo l'orario di chiusura:
5.05
0.010
+0.20%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GDRX Giù?
Forum
Previsione
Precedente Chiudi:
$4.92
Aprire:
$4.985
Volume 24 ore:
498.19K
Relative Volume:
0.34
Capitalizzazione di mercato:
$505.51M
Reddito:
$775.09M
Utile/perdita netta:
$-58.68M
Rapporto P/E:
-38.01
EPS:
-0.1326
Flusso di cassa netto:
$64.06M
1 W Prestazione:
+5.88%
1M Prestazione:
+7.46%
6M Prestazione:
+2.23%
1 anno Prestazione:
-43.43%
Intervallo 1D:
$4.985
$5.05
Intervallo di 1 settimana:
$4.68
$5.05
Portata 52W:
$3.675
$9.2599
Goodrx Holdings Inc Stock (GDRX) Company Profile
Nome
Goodrx Holdings Inc
Settore
Industria
Telefono
(855) 268-2822
Indirizzo
2701 OLYMPIC BOULEVARD, SANTA MONICA
Confronta GDRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
5.04 | 1.76B | 775.09M | -58.68M | 64.06M | -0.1326 |
|
VEEV
Veeva Systems Inc
|
286.01 | 46.61B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
64.86 | 10.57B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
HQY
Healthequity Inc
|
96.91 | 8.42B | 1.15B | 96.70M | -161.99M | 1.09 |
|
DOCS
Doximity Inc
|
61.00 | 11.13B | 550.17M | 201.35M | 232.07M | 1.00 |
|
WAY
Waystar Holding Corp
|
36.96 | 6.33B | 906.14M | -52.62M | 89.62M | -0.3621 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-04 | Iniziato | Mizuho | Neutral |
| 2024-08-09 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Iniziato | Leerink Partners | Outperform |
| 2024-01-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-08-10 | Aggiornamento | DA Davidson | Neutral → Buy |
| 2023-07-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Iniziato | Citigroup | Buy |
| 2022-11-04 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Iniziato | Truist | Hold |
| 2022-08-12 | Iniziato | DA Davidson | Neutral |
| 2022-06-10 | Downgrade | Goldman | Buy → Neutral |
| 2022-06-06 | Ripresa | BofA Securities | Buy |
| 2022-06-01 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Iniziato | Wells Fargo | Equal Weight |
| 2022-04-07 | Iniziato | Guggenheim | Buy |
| 2022-04-01 | Ripresa | Credit Suisse | Neutral |
| 2022-03-15 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Reiterato | Barclays | Overweight |
| 2022-03-01 | Reiterato | BofA Securities | Neutral |
| 2022-03-01 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-01 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Reiterato | Evercore ISI | Outperform |
| 2022-03-01 | Reiterato | Goldman | Buy |
| 2022-03-01 | Reiterato | JP Morgan | Underweight |
| 2022-03-01 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-03-01 | Reiterato | SVB Leerink | Outperform |
| 2022-01-07 | Iniziato | Goldman | Buy |
| 2021-12-21 | Iniziato | Stephens | Overweight |
| 2021-12-02 | Iniziato | Jefferies | Buy |
| 2021-08-31 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Iniziato | Robert W. Baird | Neutral |
| 2021-04-06 | Ripresa | Evercore ISI | Outperform |
| 2021-01-25 | Iniziato | Guggenheim | Buy |
| 2020-11-19 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Iniziato | Barclays | Equal Weight |
| 2020-10-19 | Iniziato | BofA Securities | Neutral |
| 2020-10-19 | Iniziato | Citigroup | Buy |
| 2020-10-19 | Iniziato | Cowen | Outperform |
| 2020-10-19 | Iniziato | Credit Suisse | Outperform |
| 2020-10-19 | Iniziato | Deutsche Bank | Hold |
| 2020-10-19 | Iniziato | Goldman | Neutral |
| 2020-10-19 | Iniziato | JP Morgan | Neutral |
| 2020-10-19 | Iniziato | Morgan Stanley | Overweight |
| 2020-10-19 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Iniziato | SVB Leerink | Outperform |
| 2020-10-19 | Iniziato | UBS | Buy |
Mostra tutto
Goodrx Holdings Inc Borsa (GDRX) Ultime notizie
What drives GoodRx Holdings Inc. stock priceDynamic investment opportunities - Autocar Professional
Jim Cramer Holds Back on GoodRx (GDRX) - MSN
Google, Meta Can't Escape GoodRx Health Data Sharing Suit - Law360
What analysts say about GoodRx Holdings Inc. stockSky-high return potential - jammulinksnews.com
GoodRx Holdings Inc. Stock Analysis and ForecastTremendous portfolio expansion - jammulinksnews.com
Is GoodRx Holdings Inc. a good long term investmentExceptional profit potential - jammulinksnews.com
GOODRX INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of GoodRx Holdings, Inc.GDRX - The Globe and Mail
Is GoodRx Holdings Inc. stock a good hedge against inflationChart Based Entries - Newser
Why GoodRx Holdings Inc. stock attracts strong analyst attentionSolid Return Trade Selections - beatles.ru
OPRX Vs. GDRX: Which Health Tech Stock Has Stronger Revenue Momentum? - Barchart.com
OPRX vs. GDRX: Which Health Tech Stock Has Stronger Revenue Momentum? - Yahoo Finance
What makes GoodRx Holdings Inc. stock price move sharplyBig Profit Small Risk Alerts - Newser
Riot Platforms selling more Bitfarms (BITF) - The Globe and Mail
Leerink Partners Remains Bullish on GoodRx Holdings (GDRX) - Insider Monkey
Undervalued Opportunities: Penny Stocks Worth Watching In July 2025 - simplywall.st
GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Average Rating of “Moderate Buy” by Analysts - Defense World
GoodRx Holdings Announces Q2 2025 Financial Results Release Date - AInvest
GoodRx Announces Date for Second Quarter 2025 Earnings Release and Conference Call - Business Wire
GDRX vs. HQY: Which Stock Is the Better Value Option? - Yahoo Finance
GoodRx: A One Big Beautiful Bill Act Beneficiary - Seeking Alpha
KeyBanc Maintains Overweight Rating on GoodRx (GDRX) - MSN
While institutions own 22% of GoodRx Holdings, Inc. (NASDAQ:GDRX), individual investors are its largest shareholders with 48% ownership - Yahoo Finance
GoodRx Holdings, Inc. (GDRX) Stock Analysis: Exploring a Potential 26.84% Upside for Investors - DirectorsTalk Interviews
GoodRx (GDRX) Unveils Lifecycle to Enhance Engineering Methodologies - Yahoo Finance
GoodRx Has New Service For ED Meds - Los Angeles Business Journal
GoodRx (GDRX) Launches a New Subscription Service for Erectile Dysfunction Treatment - Insider Monkey
GoodRx launches new subscription service focused on erectile dysfunction treatments - MSN
High Growth Tech Stocks In The US To Watch This June 2025 - simplywall.st
GoodRx (GDRX) Expands Services with New Subscription for ED Trea - GuruFocus
GoodRx (GDRX) Expands Services with New Subscription for ED Treatment | GDRX Stock News - GuruFocus
GoodRx (GDRX) Shares Rise with Launch of Erectile Dysfunction Subscription Service - GuruFocus
GoodRx stock gains on new subscription service (GDRX:NASDAQ) - Seeking Alpha
Goodrx Holdings Inc Azioni (GDRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):